NCCN pediatric neuroblastoma practice guidelines

Oncology

Volumn 10, Issue 12, 1996, Pages 1813-1822

  O'Reilly, R ^a   Cheung, N K ^a   Bowman, L ^a   Castle, V ^a   Hoffer, F ^a   Kapoor, N ^a   Kletzel, M ^a   Lindsley, K ^a   Shamberger, R ^a   Tubergen, D ^a  

^a NCCN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

CHILD; HUMAN; NEUROBLASTOMA; PRACTICE GUIDELINE; REVIEW;

EID: 0030474983     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Young JLJ, Miller RW: Incidence of malignant tumors in U.S. children. J Pediatr 86:254-258, 1975
2. Bader KL, Miller RW: US cancer incidence and mortality in the first year of life. Am J Dis Child 133:157-159, 1979.
3. Evans AE, Gerson J, Schaufer L: Spontaneous regression of neuroblastoma NCI Monogr 44-49, 1976.
4. Brodeur G, Seeger RC, Barrett A, et al: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 6:1874-1881, 1988.
5. Brodeur G, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 11:1466-1477, 1993.
6. Weinblatt ME, Heisel MA, Siegel SE: Hypertension in children with neurogenic tumors. Pediatrics 71:947, 1983.
7. Mendelsohn G, Eggleston JC, Olson JL, et al: Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest 41:144-149, 1979.
8. Mitchell WG, Snnodgrass SR: Opsoclonusataxia due to childhood neural crest tumors: A chronic neurologic syndrome. J Child Neurol 5:153, 1990.
9. Hiyama E, Yokoyama T, Ichikawa T, et al: N-myc amplification and other prognosis- associated factors in neuroblastoma. J Pediatr Surg 25(10):1095-1099, 1990.
10. Franklin IM, Pritchard J: Detection of bone marrow invasion by neuroblastoma is improved by sampling at two sites with both aspirates and trephine biopsies. J Clin Pathol 36:1215-1218, 1983.
11. Evans AE, D'Angio GJ, Randolph JA: A proposed staging for children with neuroblastoma: Children's Cancer Study Group A. Cancer 27:374-378, 1971.
12. Hayes FA, Green A, Hustu HO, et al: Surgicopathologic staging of neuroblastoma: Prognostic significance of regional lymph node metastases. Pediatrics 102:59-62, 1983.
13. Nitschke R, Smith EI, Shochat S, et al: Localized neuroblastoma treated by surgery: A Pediatric Oncology Group Study. J Clin Oncol 6:1271-1279, 1988.
14. Shimada H, Chatten J, Newton WA Jr, et al: Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglio-neuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 73:405-416, 1984.
15. Joshi VV, Cantor AB, Altshuler G, et al: Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. Cancer 69:2183-2196, 1992.
16. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985.
17. Bourhis J, Dominici C, McDowell H, et al: N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol 9:1371-1375, 1991.
18. Kaneko Y, Kanada N, Maseki N, et al: Different karyotypic patterns in early and advanced stage neuroblastomas. Cancer Res 47:311-318, 1988.
19. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and n-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol 9:581-591, 1991.
20. Fong C, White PS, Peterson K, et al: Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 52:1780-1785, 1992.
21. Hayashi Y, Inaba T, Hanada R, et al: Similar chromosomal patterns and lack of n-myc gene amplification in localized and IV-S stage neuroblastomas in infants. Med Pediatr Oncol 17:111-115, 1989.
22. Caron H: Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavorable prognostic markers in neuroblastoma. Med Pediatr Oncol XX:24:215-221, 1995.
23. Suzuki T, Bogenmann E, Shimada H, et al: Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85:377-384, 1993.
24. Nakagawara N, Nakagawara A, Scavarda NJ, et al: High expression of the TRK gene in human neuroblastoma is associated with favorable outcome: Possible role in tumor differentiation and regression. N Engl J Med 328:847-854, 1993.
25. Favrot MC, Combaret V, Lasset C: CD44-a new prognostic marker for neuroblastoma. N Engl J Med 329:1965, 1993.
26. Gross N, Beretta C, Peruisseau G, et al: CD44H expression by human neuroblastoma cells: Relation to myc-N amplification and lineage differentiation. Cancer Res 54:4238-4242, 1994.
27. Fabbretti G, Valenti C, Loda M, et al: N-myc Gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma). Hum Pathol 24:294-297, 1993.
28. Cohn SL, Look AT, Joshi VV, et al: Lack of correlation of n-myc gene amplification with prognosis in localized neuroblastoma: A Pediatric Oncology Group Study. Cancer Res 55:721-726, 1995.
29. Hasse GM, Wong KY, deLorimier AA, et al: Improvement in survival after excision of primary tumor in stage III neuroblastoma. J Pediatr Surg 24:194-200, 1989.
30. Sitarz A, Finklestein J, Grosfeld J, et al: An evaluation of the role of surgery in disseminated neuroblastoma: A report from the Children's Cancer Study Group. J Pediatr Surg 18:147-151, 1983.
31. Azizkhan RG, Shaw A, Chandler JG: Surgical complications of neuroblastoma resection. Surgery 97:514-517, 1985.
32. Le Toumeau JN, Bernard JL, Hendren WH, et al: Evaluation of the role of surgery in 130 patients with neuroblastoma. J Pediatr Surg 20:244-249, 1985.
33. Matsumura M, Atkinson JB, Hays DM, et al: An evaluation of the role of surgery in metastatic neuroblastoma. J Pediatr Surg 23:448-453, 1988.
34. LaQualia MP, Kushner BH, Heller G, et al: Stage 4 neuroblastoma diagnosed at more than one year of age: Gross total resection and clinical outcome. J Pediatr Surg 29:1162-1166, 1994.
35. Finkelstein JZ, Klemperer MR, Evans A, et al: Multiagent chemotherapy for children with metastatic neuroblastoma: A report from Children's Cancer Study Group Med Pediatr Oncol 6:179-188, 1979.
36. Ninane J, Pritchard J, Malpas JS: Chemotherapy of advanced neuroblastoma. Does adriamycin contribute? Arch Dis Child 56.544-548, 1981.
37. Hayes FA, Green AA, Mauer AM: Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma. Cancer Res 37:3766-3770, 1977.
38. West DC, Shamberger RC, Macklis RM, et al: Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 11:84-90, 1993
39. Rosen EM, Cassady JR, Frantz CN, et al: Stage IV-N: A favorable subset of children with metastatic neuroblastoma. Med Pediatr Oncol 13:194-198, 1985.
40. Rosen EM, Cassady JR, Frantz CN, et al: Improved survival in neuroblastoma using multimodality therapy. Radiother Oncol 2:189-200, 1984.
41. Deacon JM, Wilson PA, Peckham MJ: The radiobiology of neuroblastoma. Radiother Oncol 3:201-209, 1985.
42. Wheldon TE, O'Donoghue J, Gregor A, et al: Radiobiological considerations in the treatment of neuroblastoma by total body irradiation. Radiother Oncol 6:317-326, 1986.
43. Finkelstein JZ, Krailo MD, Lenarsky C, et al: 13-cis-retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: report from the Children's Cancer Study Group. Med Pediatr Oncol 20:307, 1992.
44. Villablanca JG, Avramis VI, Khan AA, et al: Phase I trial of 13-cis-retinoic acid (cis-RA) in neuroblastoma patients following bone marrow transplantation (BMT) Proc Am Soc Clin Oncol 11:366, 1992.
45. Cheung NK: Biological and Molecular Approaches to Treatment. Immunotherapy, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology, 2nd ed, pp 357-370 Philadelphia, JB Lippincott, 1992.
46. McElwain TJ, Hedley DW, Gordon MY, et al: High dose melphalan and noncryopreserved autologous bone marrow - treatment of malignant melanoma and neuroblastoma. Exp Hematol 7:360-371, 1979.
47. Treleaven JG, Ugelstad J, Philip T, et al: Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1:70-73, 1984.
48. Reynolds CP, Reynolds DA, Frenkel EP, et al: Selective toxicity of 6- hydroxydopamine and ascorbate for human neuroblastoma in vitro: A model for clearing marrow prior to autologous transplant. Cancer Res 42:1331, 1982.
49. Foreman NK, Rill DR, Coustan-Smith E. et al: Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells: Potential for residual disease eradication. Br J Cancer 67:933-938, 1993.
50. Brenner MK, Rill DR, Holladay MS, et al: Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342:1134-1137, 1993.
51. Seeger RC, Moss TJ, Feig SA, et al: Bone marrow transplantation for poor prognosis neuroblastoma, in Evans AE, D'Angio GJ, Knudsen AG, et al (eds): Advances in Neuroblastoma Research 2, pp 203-213. Progress in Clinical Biology Research, vol 271. New York, Alan R. Liss, 1988.
52. Graham-Pole J, Casper J, Elfenbein G, et al: High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Gioup Study J Clin Oncol 9:152-158, 1991.
53. Phillip T, Zucker JM, Bernard JL, et al: Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: Is cure possible in a small subgroup? J Clin Oncol 9:1037-1044, 1991.
54. Kushner BH, Gulati SC, O'Reilly RJ, et al: Autografting with bone marrow exposed to repeated courses of very high dose cyclophosphamide in vivo and to 4-hydroperoxycyclophoshamide in vitro. Med Pediatr Oncol 18:454-458, 1990.
55. Moss TJ, Cairo M, Santana VM, et al: Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation. Blood 83:3085-3089, 1994.
56. Gelfand MJ: Meta-iodobenzylguanidine in children. Semin Nucl Med 23:231-242, 1993.
57. Klingebiel T, Berthold F, Treuner J, et al: Metaiodobenzylguanidine (MIBG) in treatment of 47 patients with neuroblastoma: Results of the German Neuroblastoma Trial. Med Pediatr Oncol 19:84-88, 1991.
58. Garaventa A, Guerra P, Arrighini A, et al: Treatment of advanced neuroblastoma with I-131 meta-todobenzylguanidine. Cancer 67:922-928, 1991.
59. Voute PA, Hoefnagel CA, de Kraker J, et al: Results of treatment with 131-I- metaiodobenzylguanidine in patients with neuroblastoma. Future prospects of zetotherapy, in Evans AE, D'Angio DJ, Knudson AG, et al (eds): Advances in Neuroblastoma Research 3, pp 439-445. Progress in Clinical Biology Research, vol 366, New York, Wiley-Liss, 1991.
60. Lashford LS, Lewis U, Fielding SL, et al: Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: A United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10:1889-1896, 1992.
61. Hutchinson RJ, Sisson JC, Shapiro B, et al: 131-I-metaiodo-benzyl-guanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol 15:226-232, 1992.
62. Larson SM, Sgouros G, Cheung NK: Antibodies in cancer therapy: Radioisotope conjugates, in DeVita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer, 2nd ed, pp 534-552. Philadelphia, JB Lippicott, 1995.